Ahinsa Medico Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 5.26%
- Profit Growth -6.12%
- Ebitda 364.94%
- Net Worth 14.23%
- Total Assets -7.40%
About Ahinsa Medico
Ahinsa Medico Private Limited (AMPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 June 2013 and has a history of 11 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ruby Jain and Sambhav Jain serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51900DL2013PTC254416
- Company No.
254416
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2013
- Date of AGM
13 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Ahinsa Medico Private Limited offer?
Ahinsa Medico Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Capsules, Chocolates, Biscuits & Cookies, Cookies, Nutraceuticals & Dietary Supplements, Weight Loss Supplement, Dietary Supplements, Ayurvedic,Herbal Products & Medicine, Ayurvedic Pain Relief Oil, Psoriasis Ointment.
Who are the key members and board of directors at Ahinsa Medico?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ruby Jain  | Director | 17-Jul-2023 | Current |
| Sambhav Jain | Director | 12-Nov-2022 | Current |
Financial Performance of Ahinsa Medico.
Ahinsa Medico Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 5.26% increase. The company also saw a slight decrease in profitability, with a 6.12% decrease in profit. The company's net worth Soared by an impressive increase of 14.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ahinsa Medico?
In 2020, Ahinsa Medico had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ahinsa Medico?
Unlock and access historical data on people associated with Ahinsa Medico, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ahinsa Medico, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ahinsa Medico's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
